A new treatment
strategy has shown promise in helping to transform HIV
into a curable infection. Preliminary research published
this week in The Lancet medical journal
outlines how scientists used an anticonvulsant drug to
awaken dormant HIV hiding in the body, where it is
temporarily invisible but still dangerous.
HIV infection is
incurable because current drugs only work when the virus
is multiplying, which occurs only when it is in an active
cell. However, HIV sometimes infects dormant cells,
and when it does it becomes dormant itself. While the
virus poses no threat in its resting state, the
sleeping cells sporadically wake up, reactivating the virus
and causing it to multiply. Patients must continue to
take medications for the rest of their lives so they
can fight the virus when it comes out of the
reawakened cells. Only if every last infected dormant cell
were wiped out--or the virus purged from these
cells--could patients stop taking medication and be
virus-free, experts say.
Figuring out how
to clear this reservoir of latent infection, or whether
that's even possible, is one of the hottest areas of AIDS
research.
Over the last few
years, a handful of drugs have been shown to decrease
the size of the dormant HIV pool, but they were subsequently
abandoned because their effect was either too weak or
the side effects too toxic.
The latest drug,
valproic acid, shows more promise, said Warner Greene,
director of the Gladstone Institute for Virology and
Immunology at the University of California, San
Francisco. "It's a first baby step, showing that maybe
the use of (this type of drug)--far more likely in
combination with one or two other agents--might be a viable
approach for tackling this latency problem," said
Greene, who was not involved with the research but is
conducting similar studies. "The idea, if we could
ever do it, is to purge every latently infected cell. Treat
patients for probably two or three years, and they'd be able
to come off their antiretroviral therapy and they'd be
virus-free," he said.
The study, led by
David Margolis at the University of North Carolina at
Chapel Hill, tested the ability of valproic acid to reduce
the number of infected dormant cells. Four patients on
standard therapy were given the pills to take twice
daily for three months. The size of this pool of
infected dormant cells decreased by 75% in three out of the
four patients, the study found.
"This finding,
though not definitive, suggests that new approaches
will allow the cure of HIV in the future," Margolis said.
"It's a significant conceptual move forward." Margolis
said he believes the drug reactivates the virus inside
a dormant cell, either waking up the cell with it or
killing it.
Jean-Pierre
Routy, a professor at McGill University in Montreal, who
also studies the dormant HIV issue, said Margolis'
results were an impressive first try. "It's enormous
for just three months' treatment to have such an
effect," he said, adding that the findings merit urgent
further study. "I think it's very exciting news."
However, other
experts were less optimistic. "It's extremely unlikely
that this approach would work," said Robert Siliciano, a
professor of medicine at Johns Hopkins University who
was one of the scientists who discovered the dormant
infection problem in the mid 1990s. "It assumes
something about the mechanism which we don't know is true.
The mechanism may involve other issues that are not
affected by this drug."
"It didn't get
all the cells. That's probably because it's not really
targeting the right mechanism for latency," Siliciano said.
"It's got to be a 99.9999% reduction to be useful.
When you stop the drugs the virus explodes back so
quickly that even if you had one latently infected
cell left, in a matter of days you would be back to where
you started from."
Siliciano said he
also doubts the valproic acid approach will solve the
problem because it's likely HIV lies dormant in other types
of cells that scientists have not discovered yet, and
tackling those reservoirs may require a completely
different approach.
"It's a little
bit premature to be talking about a cure for HIV," he
said. (AP)